Becton, Dickinson and Company (NYSE:BDX) Releases Earnings Results, Beats Expectations By $0.04 EPS

Becton, Dickinson and Company (NYSE:BDX) released its earnings results on Thursday. The medical instruments supplier reported $3.96 earnings per share (EPS) for the quarter, topping the consensus estimate of $3.92 by $0.04, Zacks reports. Becton, Dickinson and Company had a return on equity of 16.23% and a net margin of 7.51%.The company had revenue of $5.89 billion for the quarter, compared to analyst estimates of $5.91 billion. During the same period in the prior year, the firm posted $3.81 EPS. Becton, Dickinson and Company’s quarterly revenue was up 8.3% on a year-over-year basis. Becton, Dickinson and Company updated its FY 2026 guidance to 14.750-15.050 EPS.

Becton, Dickinson and Company Trading Up 0.3%

Becton, Dickinson and Company stock traded up $0.49 during trading hours on Friday, hitting $177.88. The stock had a trading volume of 3,068,583 shares, compared to its average volume of 2,454,233. The business’s 50 day simple moving average is $186.77 and its 200-day simple moving average is $182.42. Becton, Dickinson and Company has a one year low of $162.29 and a one year high of $251.99. The stock has a market cap of $50.99 billion, a price-to-earnings ratio of 31.99, a P/E/G ratio of 1.42 and a beta of 0.25. The company has a quick ratio of 0.62, a current ratio of 1.10 and a debt-to-equity ratio of 0.69.

Becton, Dickinson and Company Increases Dividend

The company also recently announced a quarterly dividend, which will be paid on Wednesday, December 31st. Shareholders of record on Monday, December 8th will be issued a $1.05 dividend. This represents a $4.20 dividend on an annualized basis and a yield of 2.4%. The ex-dividend date of this dividend is Monday, December 8th. This is a boost from Becton, Dickinson and Company’s previous quarterly dividend of $1.04. Becton, Dickinson and Company’s payout ratio is currently 71.36%.

Analysts Set New Price Targets

A number of analysts have recently weighed in on the stock. Morgan Stanley upped their price target on shares of Becton, Dickinson and Company from $196.00 to $197.00 and gave the stock an “overweight” rating in a report on Monday, August 11th. Argus upped their target price on Becton, Dickinson and Company from $220.00 to $230.00 in a research note on Monday, September 15th. Stifel Nicolaus cut their target price on Becton, Dickinson and Company from $224.00 to $210.00 in a research note on Friday. Jefferies Financial Group dropped their price objective on Becton, Dickinson and Company from $257.00 to $215.00 in a research report on Friday. Finally, Wells Fargo & Company raised their price objective on Becton, Dickinson and Company from $172.00 to $184.00 and gave the company an “equal weight” rating in a research note on Friday, August 8th. Three analysts have rated the stock with a Buy rating and nine have given a Hold rating to the stock. According to data from MarketBeat, the stock has a consensus rating of “Hold” and an average price target of $203.27.

Insider Activity at Becton, Dickinson and Company

In other Becton, Dickinson and Company news, Director Claire Fraser sold 917 shares of Becton, Dickinson and Company stock in a transaction dated Wednesday, September 10th. The stock was sold at an average price of $187.50, for a total transaction of $171,937.50. Following the transaction, the director directly owned 22,226 shares of the company’s stock, valued at approximately $4,167,375. The trade was a 3.96% decrease in their position. The sale was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through this link. Also, Director Bertram L. Scott sold 217 shares of the stock in a transaction dated Friday, November 7th. The shares were sold at an average price of $176.58, for a total value of $38,317.86. Following the completion of the sale, the director directly owned 35,816 shares of the company’s stock, valued at approximately $6,324,389.28. The trade was a 0.60% decrease in their position. The disclosure for this sale is available in the SEC filing. Insiders sold 1,249 shares of company stock valued at $231,358 in the last ninety days. 0.36% of the stock is currently owned by insiders.

Hedge Funds Weigh In On Becton, Dickinson and Company

Institutional investors have recently added to or reduced their stakes in the business. Caxton Associates LLP acquired a new position in shares of Becton, Dickinson and Company during the second quarter valued at about $212,000. Oxford Asset Management LLP bought a new position in Becton, Dickinson and Company in the 2nd quarter valued at about $271,000. State of Wyoming acquired a new position in Becton, Dickinson and Company during the 2nd quarter valued at about $352,000. Teza Capital Management LLC bought a new stake in Becton, Dickinson and Company during the 2nd quarter worth approximately $379,000. Finally, Voleon Capital Management LP purchased a new stake in shares of Becton, Dickinson and Company in the second quarter worth approximately $381,000. 86.97% of the stock is owned by institutional investors and hedge funds.

About Becton, Dickinson and Company

Becton, Dickinson and Company develops, manufactures, and sells medical supplies, devices, laboratory equipment, and diagnostic products for healthcare institutions, physicians, life science researchers, clinical laboratories, pharmaceutical industry, and the general public worldwide. The company operates in three segments: BD Medical, BD Life Sciences, and BD Interventional.